Helmut R. Mäcke - Concepedia

Author

Helmut R. Mäcke

University Hospital of Basel

Also Known As

H Mäcke, H R Mäcke, H. Macke, H. Mäcke, H. R. MACKE, H. R. Macke, H. R. MÄCKE, H. R. MÄcke, H. R. Mäcke, H.R Mäcke

143

Publications

10.3K

Citations

H-Index

Concepts

All Affiliations

University Hospital of Basel University of Basel University of Bern University Medical Center Freiburg Rotterdam University of Applied Sciences

About

Helmut R. Mäcke is an author at University Hospital of Basel specializing in medicine, pharmacology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	34	4.8K
2	Engineering	19	22	2.5K
3	Biochemistry	7	7	323
4	Natural Sciences	6	6	324
5	Health Sciences	4	4	315

Helmut R. Mäcke

Publications

9.7K

Citations

H-Index

Page 1

	Year	Citations
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Jean Claude Reubi, Jean-Claude Schär, Beatrice Waser, European Journal of Nuclear Medicine and Molecular Imaging Human Somatostatin ReceptorAffinity ProfilesSomatostatin RadiotracersMedicinePathology	2000	1.1K
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [<sup>90</sup>Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers Anna Imhof, Philippe Brunner, Nicolas Marincek, Journal of Clinical Oncology	2011	616
Radiolabeled somatostatin receptor antagonists are preferable to agonists for<i>in vivo</i>peptide receptor targeting of tumors Mihaela Ginj, Hanwen Zhang, Beatrice Waser, Proceedings of the National Academy of Sciences EngineeringImmunologyPeptide SciencePharmacotherapyPeptide Therapeutics	2006	488
Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy A. Heppeler, Sylvie Froidevaux, Helmut R. Mäcke, Chemistry - A European Journal Peptide EngineeringPeptide SciencePeptide TherapeuticsInternal RadiotherapyMedicinal Chemistry	1999	332
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study Lisa Bodei, Marta Cremonesi, Stefania Zoboli, European Journal of Nuclear Medicine and Molecular Imaging Receptor-mediated Radionuclide TherapyEngineeringMedicineRadionuclide TherapyAmino Acid Infusion	2003	304
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Damian Wild, Jörg Schmitt, Mihaela Ginj, European Journal of Nuclear Medicine and Molecular Imaging Signal TransductionMedicineImmunologyReceptor (Biochemistry)Various Radiometals	2003	300
PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. Marcus Henze, Jochen Schuhmacher, Peter Hipp, PubMed Half-life AlphaEngineeringOncologic ImagingImaging AgentPet-mri	2001	266
Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy Marion de Jong, Willem H. Bakker, Eric P. Krenning, European Journal of Nuclear Medicine and Molecular Imaging Promising Somatostatin AnalogueEngineeringIndium-111 LabellingNovel TherapyMedicine	1997	212
NODAGATOC, a New Chelator-Coupled Somatostatin Analogue Labeled with [<sup>67/68</sup>Ga] and [<sup>111</sup>In] for SPECT, PET, and Targeted Therapeutic Applications of Somatostatin Receptor (hsst2) Expressing Tumors Klaus‐Peter Eisenwiener, M. Isabel M. Prata, I. Buschmann, Bioconjugate Chemistry	2002	206
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide Giovanni Paganelli, Stefania Zoboli, Marta Cremonesi, European Journal of Nuclear Medicine and Molecular Imaging Radiation TherapyRadiopharmaceutical TherapyRadiation OncologyNuclear MedicineReceptor-mediated Radiotherapy	2001	205

Page 1